-
1
-
-
27944441699
-
Multimodality approaches for pancreatic cancer
-
Yang GY, Wagner TD, Fuss M, et al. Multimodality approaches for pancreatic cancer. CA Cancer J Clin 2005;55:352-67.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 352-367
-
-
Yang, G.Y.1
Wagner, T.D.2
Fuss, M.3
-
2
-
-
84868152970
-
Pancreatic cancer: current standards, research updates and future directions
-
Hsueh CT. Pancreatic cancer: current standards, research updates and future directions. J Gastrointest Oncol 2011;2:123-5.
-
(2011)
J Gastrointest Oncol
, vol.2
, pp. 123-125
-
-
Hsueh, C.T.1
-
3
-
-
33745552215
-
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
-
Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-902.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2897-2902
-
-
Ferrone, C.R.1
Finkelstein, D.M.2
Thayer, S.P.3
-
4
-
-
58049202340
-
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704
-
Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5918-5922
-
-
Berger, A.C.1
Garcia Jr., M.2
Hoffman, J.P.3
-
5
-
-
77649280747
-
CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis
-
Tsavaris N, Kosmas C, Papadoniou N, et al. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. J Chemother 2009;21:673-80.
-
(2009)
J Chemother
, vol.21
, pp. 673-680
-
-
Tsavaris, N.1
Kosmas, C.2
Papadoniou, N.3
-
6
-
-
0032076257
-
Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy
-
Katz A, Hanlon A, Lanciano R, et al. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:393-6.
-
(1998)
Int J Radiat Oncol Biol Phys
, vol.41
, pp. 393-396
-
-
Katz, A.1
Hanlon, A.2
Lanciano, R.3
-
7
-
-
38549176328
-
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
-
Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008;9:132-8.
-
(2008)
Lancet Oncol
, vol.9
, pp. 132-138
-
-
Hess, V.1
Glimelius, B.2
Grawe, P.3
-
8
-
-
0034009704
-
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer
-
Halm U, Schumann T, Schiefke I, et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000;82:1013-6.
-
(2000)
Br J Cancer
, vol.82
, pp. 1013-1016
-
-
Halm, U.1
Schumann, T.2
Schiefke, I.3
-
9
-
-
84995748195
-
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal
-
Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012;3:105-19.
-
(2012)
J Gastrointest Oncol
, vol.3
, pp. 105-119
-
-
Ballehaninna, U.K.1
Chamberlain, R.S.2
-
10
-
-
0041564101
-
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy
-
Micke O, Bruns F, Kurowski R, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 2003;57:90-7.
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.57
, pp. 90-97
-
-
Micke, O.1
Bruns, F.2
Kurowski, R.3
-
11
-
-
61349202170
-
CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy
-
Koom WS, Seong J, Kim YB, et al. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;73:1148-54.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.73
, pp. 1148-1154
-
-
Koom, W.S.1
Seong, J.2
Kim, Y.B.3
-
13
-
-
0030968481
-
Comparing two diagnostic tests against the same "gold standard" in the same sample
-
Bloch DA. Comparing two diagnostic tests against the same "gold standard" in the same sample. Biometrics 1997;53:73-85.
-
(1997)
Biometrics
, vol.53
, pp. 73-85
-
-
Bloch, D.A.1
-
14
-
-
77649159782
-
Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival
-
Takahashi H, Ohigashi H, Ishikawa O, et al. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010;251:461-9.
-
(2010)
Ann Surg
, vol.251
, pp. 461-469
-
-
Takahashi, H.1
Ohigashi, H.2
Ishikawa, O.3
-
15
-
-
0042418394
-
Utility of tumor markers in determining resectability of pancreatic cancer
-
discussion 955-6
-
Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951-5; discussion 955-6.
-
(2003)
Arch Surg
, vol.138
, pp. 951-955
-
-
Schlieman, M.G.1
Ho, H.S.2
Bold, R.J.3
-
16
-
-
0021027153
-
Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin
-
Magnani JL, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983;43:5489-92.
-
(1983)
Cancer Res
, vol.43
, pp. 5489-5492
-
-
Magnani, J.L.1
Steplewski, Z.2
Koprowski, H.3
-
17
-
-
33846908072
-
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
-
Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-31.
-
(2007)
J Clin Oncol
, vol.25
, pp. 326-331
-
-
Huguet, F.1
André, T.2
Hammel, P.3
|